A new generation of miniature, totally implantable devices for end-stage congestive heart failure promises to return patients to normal lives. If the implantable ventricular assist devices can function reliably for many years, they may offer patients an alternative to heart transplantation and even arrest the progression of the diseases at earlier stages.
by Mary Stuart
The human heart is an amazing machine; each day, it pumps 2000 gallons of blood through 60,000 miles of vessels...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
